biostudies-literatureHis MAssociazione Italiana per la Ricerca sul Cancro-AIRC-ItalyMutuelle Générale de l’Education NationaleDutch ZONCancer Research UKFrench National Cancer InstituteHellenic Health FoundationSwedish Research CouncilCounty Councils of Skåne and VästerbottenInstitut Gustave RoussyEuropean CommissionDeutsches KrebsforschungszentrumGerman Cancer Research CenterNordic Centre of Excellence programme on Food, Nutrition and HealthRegional Governments of AndalucíaRegional Governments of AsturiasEuropean Research CouncilNordforskNational Institute for Health Research (NIHR)Dutch Ministry of Public Health, Welfare and SportsDanish Cancer SocietyFederal Ministry of Education and ResearchLigue Contre le CancerCERCA ProgramGerman Cancer AidDeutsche KrebshilfeInstitut National de la Santé et de la Recherche MédicaleNational Research CouncilInternational Agency for Research on CancerRegional Governments of Basque CountryDutch Prevention FundsWorld Cancer Research FundFondation ARCMedical Research CouncilStatistics NetherlandsNetherlands Cancer RegistrySwedish Cancer SocietyLK Research FundsRegional Governments of MurciaRegional Governments of Navarra178https://www.ebi.ac.uk/biostudies/studies/S-EPMC6757362biostudies-literatureUnknown17(1)<h4>Background</h4>Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk.<h4>Methods</h4>A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivarBMC medicineProspective analysis of circulating metabolites and breast cancer in EPIC.PMC6757362G100014310001432015-166C8221/A19170ERC-2009-AdG 2329976236NF-SI-0512-10114MR/N003284/1MR/L01341X/114136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-OxfordMR/M012190/1G0401527Postdoctoral fellowship14136C570/A16491None232997Rothwell JAFortner RTRinaldi SAgudo AViallon VSandanger TMDahm CCBoeing HSeveri GNost THSkeie GTrichopoulou ASieri STjonneland AWeiderpass EFournier ASchmidt JAGicquiau AKuhn TMartimianaki GGunter MJRiboli EChristakoudi SFerrari POvervad KMasala GSanchez MJKarakatsani Avan Gils CHTumino ROnland-Moret NCHuerta JMArdanaz EVineis PPanico SQuiros JRTsilidis KKHis MScalbert ADossus LAchaintre DRomieu IOlsen ATravis RCAmiano PfalseProspective analysis of circulating metabolites and breast cancer in EPIC.<h4>Background</h4>Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk.<h4>Methods</h4>A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivar2019-01-01T00:00:00Z2019 Sep2025-04-04T22:11:56.554Z2019-10-11T07:10:16ZS-EPMC67573623154783210.1186/s12916-019-1408-4